Investments
53Portfolio Exits
6Funds
2About Windham Venture Partners
Windham Venture Partners is a Life Sciences technology commercialization firm. The firm builds and fosters start-up companies based on research-generated technologies that originate in top U.S. and global institutions. Windham Venture Partners also act as founder, investor and initial management for these companies. The firm's approach is focused on the earliest stages of the venture capital lifecycle: company formation and providing seed capital to initiate the technology commercialization process.
Want to inform investors similar to Windham Venture Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Windham Venture Partners News
Oct 25, 2022
Alto Neuroscience , a Los Altos, CA-based neuro-tech company which specializes in precision psychiatry, raises $35M Series B Financing. The round was led by Lightswitch Capital and Alkeon Capital, with participation from Sobrato Capital, Novartis Pharma AG, Valor Equity Partners, Korify Capital, Vine Ventures, Gaingels, Apeiron Group, WhatIf Ventures, and Windham Venture Partners. In conjunction with the Series B financing, chief executive officer of Lightswitch Capital, Christopher Cox, and managing director of Alkeon Capital, Jeff Chen, Ph.D., have joined the Alto Board of Directors. Additionally, Bob Baloh, M.D., Ph.D., global head of neuroscience at the Novartis Institutes for BioMedical Research (NIBR), will join as a board observer. The company intends to use the funds to advance lead candidates into Phase 2b studies in major depressive disorder in addition to continued development on other programs within its clinical-stage precision psychiatry pipeline. Proceeds from the financing will also be used to progress the company’s artificial intelligence-enabled brain biomarker platform and launch new clinical trials in areas of high unmet medical need. Alto will report Phase 2a data in early 2023 and further anticipates Phase 2b data readouts by early 2024. Led by Amit Etkin, M.D., Ph.D., founder and chief executive officer, Alto Neuroscience provides a precision psychiatry by developing targeted medicines to help patients get better. Differences in individuals’ biology impact how they respond to treatment. Its Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, behavioral task performance, wearable data, genetics, and other factors to match each patient with the right Alto drug. The company’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, and other mental health conditions, resulting in the broadest and most-advanced precision psychiatry effort. FinSMEs 26/10/2022
Windham Venture Partners Investments
53 Investments
Windham Venture Partners has made 53 investments. Their latest investment was in Clever Care Health Plan as part of their Series C on March 3, 2023.
Windham Venture Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/15/2023 | Series C | Clever Care Health Plan | $42M | No | 3 | |
10/25/2022 | Series B | Alto Neuroscience | $35M | No | Alkeon Capital Management, Apeiron Investment Group, Gaingels, Korify Capital, Lightswitch Capital, Novartis, Sobrato Capital, Undisclosed Investors, Valor Equity Partners, Vine Ventures, What If Ventures, and Windham Venture Partners | 9 |
10/20/2022 | Series B | SubjectWell | $35M | No | 11 | |
10/7/2022 | Series B | |||||
10/4/2022 | Series B |
Date | 3/15/2023 | 10/25/2022 | 10/20/2022 | 10/7/2022 | 10/4/2022 |
|---|---|---|---|---|---|
Round | Series C | Series B | Series B | Series B | Series B |
Company | Clever Care Health Plan | Alto Neuroscience | SubjectWell | ||
Amount | $42M | $35M | $35M | ||
New? | No | No | No | ||
Co-Investors | Alkeon Capital Management, Apeiron Investment Group, Gaingels, Korify Capital, Lightswitch Capital, Novartis, Sobrato Capital, Undisclosed Investors, Valor Equity Partners, Vine Ventures, What If Ventures, and Windham Venture Partners | ||||
Sources | 3 | 9 | 11 |
Windham Venture Partners Portfolio Exits
6 Portfolio Exits
Windham Venture Partners has 6 portfolio exits. Their latest portfolio exit was Personal Genome Diagnostics on December 23, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/23/2021 | Acquired | 12 | |||
Date | 12/23/2021 | ||||
|---|---|---|---|---|---|
Exit | Acquired | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 12 |
Windham Venture Partners Fund History
2 Fund Histories
Windham Venture Partners has 2 funds, including Windham Venture Partners I LP.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
1/31/2014 | Windham Venture Partners I LP | Late-Stage Venture Capital | Closed | $20M | 1 |
Windham Venture Partners II |
Closing Date | 1/31/2014 | |
|---|---|---|
Fund | Windham Venture Partners I LP | Windham Venture Partners II |
Fund Type | Late-Stage Venture Capital | |
Status | Closed | |
Amount | $20M | |
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.